Silexion Therapeutics Corp
SLXN- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0002022416
No open-market purchases or sales by Silexion Therapeutics Corp insiders were filed in the last 90 days; 6 institutions reported holding it in 13F filings for Q2 2026, worth $42.5K in total; no superinvestor holds it.
Other share classesSLXNW
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −1 vs. previous quarter
- 6
- 13F valueReported value at the end of Q2 2026
- $42.5K
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding SLXN, Q2 2026
No superinvestor reported holding SLXN at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Silexion Therapeutics Corp insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 30, 2026 (view filing) | Mar 26 | 4 days | Shirvan MitchellCSO and CDO | SSale | −22.8K | $1.36 | −$31.0K | −45.0%27.9K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Silexion Therapeutics Corp at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| HRT Financial LP | 15,239 | $38.0K | 0.00% | +15,239 | New |
| UBS Group AG | 1,411 | $3.60K | 0.00% | +894+172.9% | Added |
| Montag A & Associates Inc | 300 | $765 | 0.00% | −2,700−90.0% | Reduced |
| Pflug Koory, LLC | 33 | $84 | 0.00% | −300−90.1% | Reduced |
| SBI Securities Co., Ltd. | 2 | $5 | 0.00% | −18−90.0% | Reduced |
| Royal Bank of Canada | 76 | $0 | 0.00% | +76 | New |